New drug combo shows promise in shrinking Hard-to-Treat breast tumors
NCT ID NCT07162051
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new drug combination (fluzoparib plus chemotherapy) given before surgery to 28 women with a specific type of early breast cancer (HR+/HER2- with HRD). The goal was to see if it could shrink tumors more effectively. The treatment was given over 8 cycles, and the main measure of success was how much tumor remained after treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HR+/HER2- EARLY BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Xijing hospital
Xi'an, Shaanxi, 710032, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Coaching may boost adherence to breast cancer therapy
- Breast cancer trial lets early response guide treatment switch
- New breast cancer trial aims to skip chemo for some patients
- Could a pill replace chemo for some breast cancer patients?
- Breast cancer drug adherence under the microscope: will patients stick with treatment?
- Coaching may boost cancer pill adherence in new study